REG - Genflow Biosciences - Director Dealings

Genflow BiosciencesAnnouncement

28/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250328:nRSb5924Ca&default-theme=true

RNS Number : 5924C  Genflow Biosciences PLC  28 March 2025

 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO
CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION
(EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN
UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS
CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

28 March 2025

 

Genflow Biosciences Plc

 

Director's Dealing

 

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company")
the only longevity company listed in Europe, is pleased to announce that it
has been notified that Dr. Eric Leire, CEO of the Company, has today purchased
2,100,000 ordinary shares in the Company at a price of 1.15 pence each on the
open market.

 

Details of the transaction are set out below:

 

 Name                                          Dr. Eric Leire
 Position                                      Chief Executive Officer
 Date of Purchase                              27 March 2025
 Number of Ordinary Shares Purchased           2,100,000
 Price per Ordinary Share                      1.15p
 Total Consideration                           £24,150
 Nature of Transaction                         Market purchase
 Total Shareholding Following the Transaction  126,514,999

 Interest in Ordinary Shares (percentage)      36.18%

 

NOTIFICATION AND PUBLIC DISCLOSURE OF A TRANSACTION BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

The following disclosure is made in accordance with the requirements of the UK
Market Abuse Regulation and provides details in relation to the purchase of
Ordinary Shares by a Director:

 

 1.  Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Eric Leire

 2.  Reason for the Notification
 a)  Position/status                                              PDMR

 b)  Initial notification / Amendment                             Initial notification

 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Genflow Biosciences Plc

 b)  LEI                                                          213800HVOFXRXVEGDN62

 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the Financial instrument, type of instrument  Ordinary Shares of £0.0003
     Identification Code                                          GB00BP2C3V08

 b)  Nature of the transaction                                    Issue of ordinary shares

 c)  Price(s) and volume(s)                                       Price(s)                       Volume(s)
                                                                  1.15 pence per Ordinary Share  2,100,000 Ordinary Shares

 d)  Aggregated information:

      Aggregated volume                                          2,100,000 Ordinary Shares

     · Price                                                      1.15 pence per Ordinary Share

 e)  Dates of the transactions                                    27 March 2025

 f)  Place of the transactions                                    London

d)

Aggregated information:

 Aggregated volume

· Price

 

2,100,000 Ordinary Shares

1.15 pence per Ordinary Share

 

 

e)

Dates of the transactions

27 March 2025

 

 

f)

Place of the transactions

London

 

Contacts

 

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32-477-495-881      +1 475 477 9401
                      Jonathan.Paterson@Harbor-access.com

 

 Corporate Brokers
 Capital Plus Partners Ltd
 Jon Critchley, +44 0203 821 6168

About Genflow Biosciences

 

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population. Genflow's lead compound, GF-1002, works through the delivery of a
centenarian variant of the SIRT6 gene which has yielded promising preclinical
results. Expected to begin in 2025, Genflow's clinical trial aims to explore
the potential benefits of GF-1002 in treating MASH (Metabolic
Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver
disease for which there is no effective treatments. Please visit
www.genflowbio.com (http://www.genflowbio.com)   and follow the Company on
LinkedIn and Twitter/X.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBCGDXDDDDGUR